Rezdiffra (Resmetirom) and Caffeine: Full Interaction Profile

What Is Resmetirom and How Is It Cleared by the Body?

Resmetirom is a liver-directed thyroid hormone receptor beta (THR-beta) agonist approved by the FDA on March 14, 2024 under the brand name Rezdiffra, making it the first pharmacological therapy approved specifically for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis stages F2 or F3 [1]. Understanding any potential caffeine interaction starts with the drug's metabolic profile.

Metabolic Pathways for Resmetirom

The FDA prescribing information for Rezdiffra identifies CYP3A4 as the primary cytochrome P450 enzyme responsible for resmetirom oxidative metabolism [1]. Beyond CYP3A4, the drug undergoes direct glucuronidation via UGT1A1 and UGT1A3, two uridine diphosphate glucuronosyltransferase isoforms concentrated in the liver [1]. Resmetirom is also a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters, which affect its intestinal and hepatic disposition [1].

None of these primary clearance routes involve CYP1A2. That single fact is the pharmacokinetic basis for the low interaction concern with caffeine.

What Resmetirom Does (and Does Not) Do to Hepatic Enzymes

The Rezdiffra prescribing information states that resmetirom inhibits OATP1B1 and OATP1B3 hepatic uptake transporters at clinically relevant concentrations, which is why co-administration with statins requires dose adjustments [1]. Resmetirom is not classified as a CYP1A2 inhibitor or inducer in the FDA label [1]. Accordingly, the drug is not expected to alter the hepatic clearance of caffeine to a clinically meaningful degree.

How Caffeine Is Metabolized: The CYP1A2 Story

Caffeine metabolism is one of the most thoroughly characterized pharmacokinetic pathways in clinical pharmacology. After oral ingestion, caffeine is absorbed nearly completely and undergoes N-demethylation to paraxanthine, theobromine, and theophylline, with paraxanthine accounting for roughly 84% of primary metabolites [2]. CYP1A2 catalyzes approximately 95% of this initial demethylation step [2].

CYP1A2 in the MASH Patient Population

CYP1A2 activity can be modestly reduced in patients with advanced hepatic fibrosis or cirrhosis. However, resmetirom is approved only for patients without cirrhosis (Metavir F2 or F3 fibrosis), a population whose CYP1A2 activity is generally preserved relative to Child-Pugh B or C patients [3]. The key MAESTRO-NASH trial enrolled patients with biopsy-confirmed MASH and F1b-to-F3 fibrosis, explicitly excluding cirrhosis [4]. This enrollment boundary is clinically meaningful because it limits the degree of baseline hepatic enzyme impairment in the approved population.

Caffeine Half-Life and Inhibitor Sensitivity

In a healthy adult, caffeine's elimination half-life ranges from 3 to 7 hours and is substantially prolonged by potent CYP1A2 inhibitors such as fluvoxamine (which can increase caffeine AUC by 5- to 10-fold) [2]. Because resmetirom does not inhibit CYP1A2, no equivalent prolongation is anticipated. Patients who are also taking fluvoxamine, ciprofloxacin, or other known CYP1A2 inhibitors should discuss that separate interaction with their prescribing clinician; resmetirom itself does not compound those risks through the same mechanism.

The CYP3A4 Angle: Does Caffeine Affect Resmetirom Exposure?

Caffeine is not a clinically significant CYP3A4 inhibitor or inducer at any dose achievable through typical dietary intake. A 2003 pharmacokinetic review published in Clinical Pharmacokinetics confirmed that caffeine's interactions are restricted almost entirely to the CYP1A2 pathway, with no meaningful CYP3A4 involvement [2]. Because resmetirom depends on CYP3A4 for oxidative clearance, caffeine is not expected to alter resmetirom plasma concentrations or area under the curve (AUC).

What Does Affect Resmetirom Exposure

By contrast, the Rezdiffra label warns that co-administration with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) or strong CYP3A4 inducers (e.g., rifampin, phenytoin) will meaningfully change resmetirom systemic exposure and that dose modification or avoidance may be required [1]. Clinicians should focus interaction counseling on those agents, not on caffeine.

The FDA's drug interaction guidance for resmetirom also identifies rosuvastatin, atorvastatin, and pravastatin as requiring dose caps due to OATP1B1/1B3 inhibition, a transporter-mediated interaction entirely separate from the CYP1A2 pathway relevant to caffeine [1].

Clinical Trial Evidence: Caffeine Was Not Restricted in MAESTRO-NASH

The MAESTRO-NASH phase 3 trial (N=966) evaluated resmetirom 80 mg and 100 mg once daily versus placebo over 52 weeks [4]. The trial's protocol, as registered on ClinicalTrials.gov (NCT03900429), did not restrict caffeine or coffee consumption among enrolled participants [5]. This is a meaningful real-world signal. If caffeine produced a clinically significant pharmacokinetic interaction with resmetirom, standard trial design would require restricting or standardizing caffeine intake to avoid exposure variability confounding the primary endpoints.

Primary Efficacy Results from MAESTRO-NASH

In MAESTRO-NASH, 25.9% of patients receiving resmetirom 80 mg achieved MASH resolution without worsening fibrosis versus 9.7% on placebo (P<0.001) [4]. For the 100 mg dose, the resolution rate was 29.9% versus 9.7% for placebo (P<0.001) [4]. Fibrosis improvement of at least one stage was observed in 24.2% (80 mg) and 25.9% (100 mg) of resmetirom-treated patients versus 14.2% on placebo [4]. These results were achieved in a population consuming caffeine ad libitum, reinforcing the absence of a meaningful clinical interaction.

The NEJM Publication and Interaction Data

The primary MAESTRO-NASH results were published in the New England Journal of Medicine in 2024 [4]. The published manuscript does not report any subgroup analysis or adverse event signal attributable to caffeine co-consumption, consistent with the absence of a pharmacokinetic basis for such an effect.

Caffeine and MASH: Separate Biology Worth Knowing

This section addresses a distinct question from the interaction profile. Caffeine consumption is not the same as an interaction with resmetirom. However, patients on Rezdiffra frequently ask whether coffee is safe or even beneficial given their diagnosis.

Observational Evidence on Coffee and Liver Fibrosis

A meta-analysis of 16 studies (N=3,153) published in Alimentary Pharmacology and Therapeutics found that habitual coffee consumption was associated with a reduced risk of liver fibrosis progression in patients with nonalcoholic fatty liver disease, with an odds ratio of approximately 0.71 (95% CI 0.56-0.89) [6]. A separate analysis published in Clinical Gastroenterology and Hepatology involving 306 patients with biopsy-confirmed NAFLD found that coffee drinkers consuming two or more cups per day had significantly lower fibrosis scores compared with non-drinkers [7].

The proposed mechanisms include caffeine-independent effects of coffee polyphenols (particularly chlorogenic acids) on hepatic stellate cell activation, as well as caffeine's ability to increase hepatic cyclic adenosine monophosphate (cAMP) and suppress transforming growth factor-beta (TGF-beta) signaling [6].

What This Means for Rezdiffra Patients

Habitual moderate coffee consumption is not contraindicated in patients taking resmetirom. No pharmacokinetic rationale supports restriction. The observational hepatoprotective signal, while not causal or sufficient to replace therapy, does not conflict with resmetirom's mechanism of action. Patients should be advised to follow standard caffeine intake guidance (generally up to 400 mg per day in healthy adults per the FDA's informal guidance [8]) and flag any symptoms potentially attributable to caffeine sensitivity, which would be independent of resmetirom.

Alcohol and Rezdiffra: A Separate and More Consequential Question

Patients often ask about both caffeine and alcohol together. Alcohol is a substantively different concern from caffeine in MASH management.

Why Alcohol Matters in MASH

The American Association for the Study of Liver Diseases (AASLD) practice guidance states that patients with MASH and significant fibrosis should be counseled to abstain from alcohol or limit intake to the absolute minimum, given alcohol's direct hepatotoxic and fibrogenic effects [9]. Resmetirom does not have a pharmacokinetic interaction with ethanol mediated through shared CYP pathways in the same way that some hepatically metabolized drugs do, but the combination is clinically inadvisable for disease-management reasons [1].

Alcohol is primarily cleared by alcohol dehydrogenase (ADH) and, at higher doses, by CYP2E1. Resmetirom is not a CYP2E1 substrate, inhibitor, or inducer [1]. Nevertheless, the Rezdiffra prescribing information instructs clinicians to monitor hepatic function, and alcohol adds independent hepatotoxic burden that complicates that monitoring and could accelerate fibrosis in patients for whom resmetirom is intended to reverse it [1, 9].

Practical Counseling Point

The practical message for patients: caffeine requires no restriction, while alcohol requires a direct conversation with the prescribing clinician about abstinence or strict limitation. These two substances occupy completely different risk tiers in MASH management.

Drug-Drug Interactions That Actually Require Attention With Resmetirom

For completeness, the interactions that carry real clinical weight in patients on resmetirom are worth summarizing so clinicians can prioritize counseling appropriately.

Statin Co-Administration

Because resmetirom inhibits OATP1B1 and OATP1B3 hepatic uptake transporters, it significantly increases plasma exposure of statins that depend on these transporters for hepatic clearance [1]. The Rezdiffra label specifies that rosuvastatin doses should not exceed 20 mg daily, atorvastatin should not exceed 40 mg daily, and simvastatin should not exceed 20 mg daily when co-administered with resmetirom [1]. Pravastatin AUC increases approximately 2.3-fold with resmetirom co-administration [1]. These are the interactions that require active dose adjustments at the time of prescribing.

Strong CYP3A4 Modulators

Co-administration of resmetirom with strong CYP3A4 inhibitors such as clarithromycin or ketoconazole is expected to increase resmetirom AUC substantially. Strong inducers such as rifampin may decrease resmetirom exposure below therapeutic levels [1]. Clinical judgment and possible dose modification are required in these scenarios.

P-glycoprotein Inhibitors

Resmetirom is a P-gp substrate. P-gp inhibitors (e.g., verapamil, amiodarone, dronedarone) may increase resmetirom intestinal absorption and systemic exposure, warranting monitoring for dose-dependent adverse effects including elevated liver enzymes or GI symptoms [1].

Resmetirom Pharmacokinetics at a Glance: Interaction Risk Table

The table below summarizes resmetirom's interaction risk by metabolic pathway, rated by clinical evidence level. Caffeine appears in the low-risk category because it neither inhibits nor induces any pathway relevant to resmetirom clearance.

| Pathway | Relevant Co-Medications | Caffeine Involvement | Clinical Action | |---|---|---|---| | CYP3A4 substrate | Clarithromycin, rifampin, itraconazole | None | Dose adjust or avoid | | OATP1B1/B3 inhibitor | Rosuvastatin, atorvastatin, pravastatin | None | Statin dose caps per label | | P-gp substrate | Verapamil, amiodarone | None | Monitor for toxicity | | CYP1A2 (caffeine's route) | Fluvoxamine, ciprofloxacin | Primary | No resmetirom effect | | UGT1A1/1A3 substrate | Rifampin (inducer), atazanavir (inhibitor) | None | Clinical judgment |

Monitoring Recommendations for Patients on Resmetirom

The Rezdiffra prescribing information recommends obtaining liver function tests (ALT, AST) before initiating therapy and monitoring periodically during treatment [1]. Discontinuation is recommended if ALT or AST exceeds 5 times the upper limit of normal or if signs of liver injury appear [1].

Caffeine consumption does not affect ALT or AST in a clinically meaningful way in most patients and will not confound hepatic monitoring. A 2017 study in the European Journal of Nutrition found no significant effect of moderate caffeine intake (up to 400 mg daily) on transaminase levels in otherwise healthy adults [10].

Patients should report new symptoms such as right upper quadrant discomfort, jaundice, or dark urine to their prescribing provider promptly, as these may signal hepatic adverse events that require laboratory evaluation independent of caffeine intake [1].

Resmetirom Dosing Context

Resmetirom is approved at 80 mg once daily for patients with body weight below 100 kg and 100 mg once daily for patients with body weight of 100 kg or more, administered with food [1]. The drug is taken as a single oral tablet. No dose adjustment is required based on caffeine co-administration. Food increases resmetirom bioavailability and reduces peak concentration variability [1], so consistent administration with meals is encouraged regardless of whether the meal or beverage includes caffeinated coffee or tea.